drugset / Trial / NCT03225287

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

NCT03225287

Phase 2 Terminated 19 enrolled Ra Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.

Timeline

Start
2017-07-17
Primary completion
2021-09-07
Completion
2021-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Zilucoplan Peptide